TAG72 CAR-T therapy for recurrent epithelial ovarian cancer
Official title: A Phase 1 Study to Evaluate Chimeric Antigen Receptor (CAR) T cells Targeting TAG72 in Patients with Recurrent Epithelial Ovarian Cancer
Funded at Beckman Research Institute/city of Hope · NIH-11384880 · Data updated 2026-11-12
A targeted CAR-T cell therapy delivered into the abdomen for women with recurrent epithelial ovarian cancer to attack cancer cells expressing TAG72.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Beckman Research Institute/city of Hope NIH-funded |
| Lab location | 1 site (Duarte, United States) |
| Project start | September 1, 2022 |
| Project end | June 30, 2027 |
| Funding year | 2026 |
| Award (this year) | $704,036 |
| NIH project number | 5R01CA266874-05 |
| Project ID | NIH-11384880 on NIH RePORTER |
Who could benefit from this research
✓Could help
Patients with recurrent epithelial ovarian cancer whose tumors express TAG72 and who can tolerate regional (intraperitoneal) CAR-T cell delivery.
✕Less likely to help
Patients whose tumors do not express TAG72 or who cannot undergo intraperitoneal therapy may not benefit from this approach.
What this research studies
This grant supports a first-in-human evaluation of CAR T cells engineered to recognize TAG72, a marker found on many ovarian cancers. The study focuses on delivering the therapy regionally inside the abdomen to overcome barriers of the tumor environment and improve T cell activity. Patients will be closely monitored for safety, immune response, and signs of tumor control. If successful, this approach could offer a new treatment option for those with limited current choices and potentially extend survival.
Why it matters
Potential benefit: If successful, patients could experience tumor reduction and longer survival with a treatment tailored to their cancer’s specific target.
How similar studies have gone: Preclinical and early work suggests regional delivery of TAG72-targeted CAR T cells can have superior anti-tumor activity, but clinical evidence in ovarian cancer is limited.
Where this research is happening
-
Beckman Research Institute/city of Hope
Duarte, United States Active
Researchers
- Principal investigator: Rodriguez-Rodriguez, Lorna — Beckman Research Institute/city of Hope
- Study coordinator: Rodriguez-Rodriguez, Lorna
Related research
Other NIH-funded projects on the same topics.
-
Liquid biopsy clues: plasma bacteria as early warning for epithelial ovarian cancer
A patient-friendly look at a new approach that uses tiny bacteria signals in blood to help detect ovarian cancer early.
-
Understanding how cancer cells talk to the immune system and how to use that to treat ovarian cancer
This grant studies how aging-like changes in ovarian cancer cells drive harmful signals and tests new ways to block those signals to improve treatment.
-
Targeting the immune system to help treat recurrent ovarian cancer
Aims to test a new approach that blocks a part of the immune system (complement) to boost anticancer immunity in people with recurrent ovarian cancer and fluid buildup.
-
Th17-inducing vaccine plus pembrolizumab for recurrent ovarian cancer
A phase I/II study tests a vaccine that activates Th17 immune cells together with pembrolizumab to help fight recurrent ovarian cancer.
-
CAR T-cell therapy targeting TAG72 for recurrent epithelial ovarian cancer
This trial tries a CAR T‑cell treatment that targets the TAG72 protein for people with recurrent epithelial ovarian cancer, given directly into the abdomen.
-
How fat use changes make ovarian cancer more invasive and chemo‑resistant
This project looks at whether shifts in how ovarian cancer cells use fats make them more likely to spread and resist chemotherapy for people with epithelial ovarian cancer.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.